Site News

Added 14 hours ago Drug news

EU CHMP recommends Trumenba (Meningococcal Group B Vaccine) immunization of individuals 10 years and older to prevent invasive meningococcal disease . - Pfizer

Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...

Added 1 day ago Drug news

FDA approves Symproic (naldemedine) to treat opioid-induced constipation.- Shionogi + Purdue Pharma

Shionogi Inc. and Purdue Pharma L.P. announced that the FDA approved Symproic (naldemedine) 0.2 mg tablets C-II as a once-daily...

Added 1 day ago Drug news

EU Commission approves Amgevita (biosimilar adalimumab) for all indications of the originator drug.- Amgen.

Amgen has announced that the European Commission (EC) has granted marketing authorization for Amgevita (biosimilar adalimumab) in all available indications....

Added 1 day ago Drug news

FDA grants accelerated approval for Bavencio (avelumab)to treat Merkel cell carcinoma .-Merck KgAA + Pfizer

Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) Injection 20 mg/mL, for intravenous use, for the...

Added 1 day ago Drug news

CHMP recommends approval of Keytruda (pembrolizumab), for relapsed or refractory classical Hodgkin lymphoma- Merck Inc

Merck Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

Added 3 days ago Drug news

Data from ABSORB III study showed that Absorb Bioresorbable Vascular Stent was comparable in efficacy to the Xience metallic drug-eluting stent-Abbott

Abbott has announced that data from the ABSORB III U.S. pivotal trial showed that Absorb, Abbott's first-of-its-kind dissolving stent, had...

Added 3 days ago Drug news

Successful Phase III trial of Ameluz (5-aminolevulinic acid) with photodynamic therapy to treat actinic keratosis.- Biofrontera AG

Biofrontera AG announced detailed results from its Phase III clinical trial evaluating the safety and efficacy of its topical prescription...

Added 3 days ago Drug news

RLX 030 (serelaxin) fails to meet endpoints of reduction of cardiovascular death or worsening heart failure in RELAX-AHF-2.- Novartis

Novartis announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX 030 (serelaxin)...

Added 4 days ago Drug news

New data from Novartis suggests that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.

Novartis has announced new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis...

Added 5 days ago Drug news

Positive results from SUMMIT-07 Phase III efficacy study of NKTR-181, a first-in-class opioid analgesic.- Nektar Therapeutics

Nektar Therapeutics announced positive results from the SUMMIT-07 Phase III efficacy study of NKTR-181, a first-in-class opioid analgesic. The SUMMIT-07...

View all news articles